SCHEMBL2431864

SCHEMBL2431864

N#Cc1c(N)ccc(C(F)(F)F)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.39
GAA P10253 9/20 0.36
ALDH1A1 P00352 9/20 0.36
KDM4E B2RXH2 8/20 0.36
HTT P42858 3/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 1/20 0.36
CUL4A Q13619 1/20 0.35
GLA P06280 7/20 0.34
HPGD P15428 7/20 0.34
TP53 P04637 1/20 0.34
POLB P06746 3/20 0.32
LMNA P02545 2/20 0.32
NCOA1 Q15788 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HIF1A Q16665 1/20 0.32
NCOA3 Q9Y6Q9 1/20 0.32
MEN1 O00255 1/20 0.32
CRHBP P24387 1/20 0.32
CRHR2 Q13324 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16936653 0.77 KIF11 (0.39) KIF11GAAALDH1A1KDM4EHTT
SCHEMBL29196717 0.75 TRPV4 (0.37) GAAALDH1A1CUL4ALMNA
SCHEMBL922455 0.74 KIF11 (0.41) KIF11GAAALDH1A1GLAPOLB
SCHEMBL2417258 0.74 CUL4A (0.46) GAAALDH1A1KDM4EHTTKMT2A
SCHEMBL9821205 0.74 CCNA2 (0.32) SMN1; SMN2ARTSHR
SCHEMBL25983203 0.74 KIF11 (0.44) KIF11GAAALDH1A1KDM4EHTT
SCHEMBL7920588 0.73 KIF11 (0.42) KIF11GAAALDH1A1KDM4EHTT
SCHEMBL25983339 0.73 ALDH1A1 (0.43) KIF11GAAALDH1A1KDM4EHTT
SCHEMBL438369 0.73 KIF11 (0.39) KIF11GAAALDH1A1GLAPOLB
SCHEMBL406265 0.72 KDM4E (0.37) GAAALDH1A1KDM4EHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
WO-2011112731-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-15 WO disclosed
WO-2011112731-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-15 WO disclosed
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-05-13 US disclosed
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-05-13 US disclosed
WO-2010030785-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS INC. (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 KIF11 4724/4885GAA 3072/4885ALDH1A1 1909/4885
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 KIF11 4724/4885GAA 3072/4885ALDH1A1 1909/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 KIF11 4724/4885GAA 3072/4885ALDH1A1 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.